Pfizer Discontinues Gene Therapy for Hemophilia B

FOR IMMEDIATE RELEASE

The Coalition for Hemophilia B Responds to Pfizer’s Discontinuation of Gene Therapy for Hemophilia B

New York – February 20, 2025 – The Coalition for Hemophilia B, a leading nonprofit dedicated to advocating for individuals with Hemophilia B, acknowledges Pfizer’s recent decision to discontinue the global development and commercialization of its gene therapy, Beqvez, for Hemophilia B.

Kim Phelan, CEO of The Coalition for Hemophilia B, stated:

“While we are disappointed to learn of this discontinuation, we respect Pfizer’s decision as they evaluate their portfolio and future direction. Pfizer has been a long-standing partner in advancing treatments for the bleeding disorders community, and we appreciate their continued commitment to innovative therapies.

“Importantly, we remain hopeful and reassured that individuals with Hemophilia B still have access to an approved gene therapy option, HEMGENIX® by CSL Behring, which received FDA approval in November 2022. Many patients undergoing this therapy have experienced significant success, and we are grateful that this lifesaving treatment remains available.”

As an organization, we are committed to supporting our community through these transitions and ensuring that individuals with Hemophilia B continue to have access to the best possible care and treatment options. We encourage patients to speak with their healthcare providers about the best path forward and will continue to provide updates as more information becomes available.

For more information, please contact:

Kimberly Phelan
CEO
Kimp@hemob.org
Hemob.org